About this Journal Submit a Manuscript Table of Contents
Mediators of Inflammation
Volume 6 (1997), Issue 2, Pages 119-126
http://dx.doi.org/10.1080/09629359791811

Pentoxifylline inhibits the fibrogenic activity of pleural effusions and transforming growth factor-β

1Medizinische Klinik, Forschungszentrum Borstel, Parkallee 35, Borstel 23845, Germany
2Institutsbereich Immunologie und Zellbiologie, Forschungszentrum Borstel, Germany
3Institut für Medizinische Molekularbiologie, Medizinische Universitaät Lübeck, Germany

Copyright © 1997 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Physiopathology of organ fibrosis is far from being completely understood, and the efficacy of the available therapeutic strategies is disappointing. We chose pleural disease for further studies and addressed the questions of which cytokines are relevant in pleural fibrosis and which drugs might interrupt its development. We screened pleural effusions for mediators thought to interfere with fibrogenesis (transforming growth factor-β (TGF-β), tumour necrosis factor α (TNFα), soluble TNF-receptor p55 (sTNF-R)) and correlated the results with patient clinical outcome in terms of extent of pleural thickenings. We found pleural thickenings correlated with TGF-β (p<0.005) whereas no correlations could be observed with TNFα and sTNF-R. Further, we were interested in finding out how TGF-β effects on fibroblast growth could be modulated. We found that pentoxifylline is able to inhibit both fibroblast proliferation and collagen synthesis independently of the stimulus. We conclude that, judging from in vitro studies, pentoxifylline might offer a new approach in the therapy of pleural as well as pulmonary fibrosis.